Matthew Simon

Matt Simon is a Principal Scientist at Denali Therapeutics interested in drug delivery to the CNS and RNA based therapeutic strategies for neurodegenerative diseases. Matt received his PhD in neuroscience at Oregon Health & Science University, studying brain-CSF interactions in aging and neurodegeneration. He has been at Denali Therapeutics for 6 years, using in vivo models of neurodegeneration to investigate brain penetrant therapeutic strategies, and profile disease mechanisms and biomarkers. His current research focuses on the delivery and impact of RNA modifying therapeutics for treatment of CNS diseases.